A detailed history of Victory Capital Management Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 33,184 shares of RNA stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,184
Previous 21,817 52.1%
Holding current value
$1.09 Million
Previous $891,000 71.04%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$37.21 - $48.14 $422,966 - $547,207
11,367 Added 52.1%
33,184 $1.52 Million
Q2 2024

Aug 05, 2024

BUY
$22.73 - $40.85 $284,056 - $510,502
12,497 Added 134.09%
21,817 $891,000
Q1 2024

May 03, 2024

BUY
$9.16 - $25.52 $85,371 - $237,846
9,320 New
9,320 $237,000
Q3 2022

Nov 02, 2022

BUY
$15.46 - $23.43 $5,596 - $8,481
362 Added 1.86%
19,842 $324,000
Q2 2022

Aug 01, 2022

BUY
$11.18 - $20.5 $4,326 - $7,933
387 Added 2.03%
19,480 $283,000
Q1 2022

May 04, 2022

SELL
$14.2 - $23.78 $3,791 - $6,349
-267 Reduced 1.38%
19,093 $273,000
Q4 2021

Feb 07, 2022

SELL
$20.4 - $28.66 $64,321 - $90,364
-3,153 Reduced 14.01%
19,360 $460,000
Q3 2021

Nov 02, 2021

SELL
$18.16 - $25.21 $18.8 Million - $26.1 Million
-1,034,799 Reduced 97.87%
22,513 $554,000
Q2 2021

Aug 03, 2021

BUY
$19.62 - $29.26 $691,722 - $1.03 Million
35,256 Added 3.45%
1,057,312 $26.1 Million
Q1 2021

May 04, 2021

BUY
$20.28 - $28.15 $3.42 Million - $4.75 Million
168,764 Added 19.78%
1,022,056 $22.3 Million
Q4 2020

Feb 01, 2021

BUY
$24.73 - $35.12 $1.23 Million - $1.75 Million
49,925 Added 6.21%
853,292 $21.8 Million
Q3 2020

Nov 09, 2020

SELL
$23.35 - $35.94 $2.04 Million - $3.14 Million
-87,413 Reduced 9.81%
803,367 $22.6 Million
Q2 2020

Aug 07, 2020

BUY
$26.62 - $31.5 $23.7 Million - $28.1 Million
890,780 New
890,780 $25.2 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.71B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.